Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 0.00 | 210.00K | 2.47B | 512.50K | 0.00 |
Gross Profit | 0.00 | 49.00K | 2.47B | 127.50K | -90.16K |
EBITDA | -12.66M | -10.96M | -13.73M | -13.08M | -10.00M |
Net Income | -12.55M | -9.81M | -13.49M | -12.95M | -10.13M |
Balance Sheet | |||||
Total Assets | 21.59M | 25.52M | 30.41M | 36.26M | 9.45M |
Cash, Cash Equivalents and Short-Term Investments | 19.92M | 23.84M | 29.69M | 35.73M | 9.06M |
Total Debt | 232.00K | 175.00K | 221.00K | 259.48K | 55.20K |
Total Liabilities | 2.70M | 2.15M | 2.21M | 1.49M | 1.19M |
Stockholders Equity | 20.00M | 24.34M | 29.05M | 35.44M | 8.76M |
Cash Flow | |||||
Free Cash Flow | -7.33M | -6.21M | -6.49M | -4.94M | -6.19M |
Operating Cash Flow | -7.33M | -6.21M | -6.49M | -4.94M | -6.18M |
Investing Cash Flow | 4.28M | -5.60M | -10.73M | -3.92M | -305.79K |
Financing Cash Flow | 3.42M | 366.00K | 452.00K | 31.57M | 9.41M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.81B | -0.22 | -40.01% | 2.29% | 21.48% | -2.11% | |
49 Neutral | $96.31M | ― | -61.14% | ― | ― | -2.11% | |
49 Neutral | $92.72M | 20.31 | 503.05% | ― | 13.54% | ― | |
39 Underperform | $274.81M | ― | -29.24% | ― | ― | -125.92% | |
38 Underperform | $89.89M | ― | 0.00% | ― | ― | ― | |
36 Underperform | $100.15M | ― | -41.66% | ― | ― | -8.91% | |
― | $169.90M | ― | ― | ― | ― |
Anixa Biosciences, in collaboration with Cleveland Clinic, unveiled promising results from their Phase 1 trial of a breast cancer vaccine aimed at triple-negative breast cancer (TNBC). The vaccine, based on groundbreaking research, showed safety and efficacy in activating immune responses in patients. As they gear up for a Phase 2 study in 2025, the vaccine’s potential to become a preventive measure against aggressive breast cancer offers hope for future treatments and partnerships with major pharmaceutical firms.